Johnson Wendy S.
Known title: DirectorCIK: 0001652822
Johnson Wendy S.'s purchase track record
Johnson Wendy S. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/3/2021 | XGN | $14K | -31.7% | -46.7% | -4.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| XGN | ▲ Buy | Open Market | 1,000 | $14K | 9/3/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
TD Cowen Raises Exagen Price Target to $11
TD Cowen has maintained its positive stance on Exagen, raising its price target to $11. This update aligns with the broader analyst consensus, where the average target sits at $10.14. The move provides context for the stock's current position within its 52-week range of $2.59 to $12.23.
TD Cowen Raises Exagen Price Target to $11. TD Cowen has maintained its positive stance on Exagen, raising its price target to $11. This update aligns with the broader analyst consensus, where the average target sits at $10.14. The move provides context for the stock's current position within its 52-week range of $2.59 to $12.23.